Lazarus Alon 4
4 · Keros Therapeutics, Inc. · Filed Apr 13, 2020
Insider Transaction Report
Form 4
Lazarus Alon
Director10% Owner
Transactions
- Conversion
Common Stock
2020-04-13+1,382,295→ 1,382,295 total(indirect: See footnote) - Purchase
Common Stock
2020-04-13$16.00/sh+120,000$1,920,000→ 2,013,102 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2020-04-13−1,382,295→ 0 total(indirect: See footnote)→ Common Stock (1,382,295 underlying) - Conversion
Common Stock
2020-04-13+343,270→ 1,725,565 total(indirect: See footnote) - Conversion
Series B-1 Preferred Stock
2020-04-13−343,270→ 0 total(indirect: See footnote)→ Common Stock (343,270 underlying) - Conversion
Common Stock
2020-04-13+167,537→ 1,893,102 total(indirect: See footnote) - Conversion
Series C Preferred Stock
2020-04-13−167,537→ 0 total(indirect: See footnote)→ Common Stock (167,537 underlying)
Holdings
- 23,038
Common Stock
Footnotes (2)
- [F1]Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.
- [F2]The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. The Reporting Person, a member of the board of directors of the Issuer, is the Biotech Investment Manager of the Pharma Division of Arkin Holdings, and, as a result, may be deemed to share voting and investment power with respect to the shares held by Arkin Bio. The Reporting Person disclaims beneficial ownership of the shares held by Arkin Bio, except to the extent of his pecuniary interest therein.